PT2318375E - Imidazole carboxamidas - Google Patents

Imidazole carboxamidas Download PDF

Info

Publication number
PT2318375E
PT2318375E PT09790351T PT09790351T PT2318375E PT 2318375 E PT2318375 E PT 2318375E PT 09790351 T PT09790351 T PT 09790351T PT 09790351 T PT09790351 T PT 09790351T PT 2318375 E PT2318375 E PT 2318375E
Authority
PT
Portugal
Prior art keywords
methyl
compound
trifluoromethyl
mmol
pharmaceutically acceptable
Prior art date
Application number
PT09790351T
Other languages
English (en)
Portuguese (pt)
Inventor
Deyi Zhang
Albert Khilevich
Bin Liu
Daniel Ray Mayhugh
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2318375E publication Critical patent/PT2318375E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/91Nitro radicals
    • C07D233/92Nitro radicals attached in position 4 or 5
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
PT09790351T 2008-07-18 2009-07-14 Imidazole carboxamidas PT2318375E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8177408P 2008-07-18 2008-07-18

Publications (1)

Publication Number Publication Date
PT2318375E true PT2318375E (pt) 2012-10-22

Family

ID=41128155

Family Applications (1)

Application Number Title Priority Date Filing Date
PT09790351T PT2318375E (pt) 2008-07-18 2009-07-14 Imidazole carboxamidas

Country Status (19)

Country Link
US (1) US7754742B2 (enExample)
EP (1) EP2318375B1 (enExample)
JP (1) JP5379227B2 (enExample)
KR (1) KR101287713B1 (enExample)
CN (1) CN102099344B (enExample)
AR (1) AR074631A1 (enExample)
BR (1) BRPI0915977A2 (enExample)
CA (1) CA2731215C (enExample)
CY (1) CY1113315T1 (enExample)
DK (1) DK2318375T3 (enExample)
EA (1) EA018434B1 (enExample)
ES (1) ES2393243T3 (enExample)
HR (1) HRP20120830T1 (enExample)
MX (1) MX2011000611A (enExample)
PL (1) PL2318375T3 (enExample)
PT (1) PT2318375E (enExample)
SI (1) SI2318375T1 (enExample)
TW (1) TW201006801A (enExample)
WO (1) WO2010009062A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI417095B (zh) 2006-03-15 2013-12-01 Janssen Pharmaceuticals Inc 1,4-二取代之3-氰基-吡啶酮衍生物及其作為mGluR2-受體之正向異位性調節劑之用途
TW200900065A (en) 2007-03-07 2009-01-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives
TW200845978A (en) 2007-03-07 2008-12-01 Janssen Pharmaceutica Nv 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives
KR20100080597A (ko) 2007-09-14 2010-07-09 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 1,3-이치환된-4-페닐-1h-피리딘-2-온
CA2696948C (en) 2007-09-14 2013-04-30 Jose Maria Cid-Nunez 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h,1'h-[1,4']bipyridinyl-2'-ones
CA2735764C (en) 2008-09-02 2016-06-14 Ortho-Mcneil-Janssen Pharmaceuticals, Inc. 3-azabicyclo[3.1.0]hexyl derivatives as modulators of metabotropic glutamate receptors
AU2009304293B2 (en) 2008-10-16 2012-04-26 Addex Pharma S.A. Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors
MY153913A (en) 2009-05-12 2015-04-15 Janssen Pharmaceuticals Inc 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EA020671B1 (ru) 2009-05-12 2014-12-30 Янссен Фармасьютикалз, Инк. ПРОИЗВОДНЫЕ 1,2,4-ТРИАЗОЛО[4,3-a]ПИРИДИНА И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ПОЛОЖИТЕЛЬНЫХ АЛЛОСТЕРИЧЕСКИХ МОДУЛЯТОРОВ РЕЦЕПТОРОВ mGluR2
NZ596078A (en) 2009-05-12 2013-06-28 Janssen Pharmaceuticals Inc 1,2,4-TRIAZOLO [4,3-a] PYRIDINE DERIVATIVES AND THEIR USE FOR THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS
EP2643320B1 (en) 2010-11-08 2015-03-04 Janssen Pharmaceuticals, Inc. 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
CN103298810B (zh) 2010-11-08 2016-03-16 杨森制药公司 1,2,4-三唑并[4,3-a]吡啶衍生物及其作为MGLUR2受体的正变构调节剂的用途
CA2815002C (en) 2010-11-08 2019-10-22 Janssen Pharmaceuticals, Inc. 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors
EP2681196B1 (en) 2011-03-04 2015-09-09 Life Technologies Corporation Compounds and methods for conjugation of biomolecules
WO2012131539A1 (en) 2011-03-31 2012-10-04 Pfizer Inc. Novel bicyclic pyridinones
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
JO3368B1 (ar) 2013-06-04 2019-03-13 Janssen Pharmaceutica Nv مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2
JO3367B1 (ar) 2013-09-06 2019-03-13 Janssen Pharmaceutica Nv مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2
LT3431106T (lt) 2014-01-21 2021-02-10 Janssen Pharmaceutica Nv Deriniai, apimantys 2 potipio metabotropinio glutamaterginio receptoriaus teigiamus alosterinius moduliatorius arba ortosterinius agonistus, ir jų panaudojimas
KR102414246B1 (ko) 2014-01-21 2022-06-27 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
TN2017000342A1 (en) 2015-02-03 2019-01-16 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
CN107207449B (zh) 2015-04-23 2020-11-10 豪夫迈·罗氏有限公司 用于治疗精神障碍的四唑衍生物
CN104788694B (zh) * 2015-04-29 2018-06-08 江苏亚宝绝缘材料股份有限公司 一种超低收缩率的聚酰亚胺薄膜
EP3359537B1 (en) 2015-10-06 2020-03-25 H. Hoffnabb-La Roche Ag Triazole derivatives
JP6905988B2 (ja) 2016-02-02 2021-07-21 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Eaat3阻害剤としてのピラゾール−ピリジン誘導体
CN109071451B (zh) 2016-05-27 2022-07-15 豪夫迈·罗氏有限公司 作为eaat3抑制剂的吡唑化合物
EP3526201B1 (en) 2016-10-14 2020-11-18 H. Hoffnabb-La Roche Ag Imidazole compounds as eaat3 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE7897T1 (de) 1979-09-05 1984-06-15 Glaxo Group Limited Phenol-derivate, verfahren zu ihrer herstellung und sie enthaltende pharmazeutische zusammensetzungen.
US4666928A (en) 1984-08-30 1987-05-19 Merck Frosst Canada, Ind. Propylphenoxy pyridine carboxylates as leukotriene antagonists
TW204343B (enExample) 1991-05-31 1993-04-21 Sumitomo Pharmaceutics Co Ltd
US6800651B2 (en) 2000-02-03 2004-10-05 Eli Lilly And Company Potentiators of glutamate receptors
JP2006502143A (ja) 2002-08-26 2006-01-19 メルク エンド カムパニー インコーポレーテッド 向代謝型グルタミン酸受容体のアセトフェノン増強因子
WO2006014918A2 (en) * 2004-07-30 2006-02-09 Merck & Co., Inc. Heterocyclic acetophenone potentiators of metabotropic glutamate receptors
AU2005267883A1 (en) 2004-07-30 2006-02-09 Merck & Co., Inc. Indanone potentiators of metabotropic glutamate receptors
TW200613272A (en) 2004-08-13 2006-05-01 Astrazeneca Ab Isoindolone compounds and their use as metabotropic glutamate receptor potentiators
AU2005299797A1 (en) 2004-10-25 2006-05-04 Merck & Co., Inc. Heterocyclic indanone potentiators of metabotropic glutamate receptors
ES2333979T3 (es) * 2004-11-22 2010-03-03 Eli Lilly And Company Potenciadores de los receptores del glutamato.
CN101128435A (zh) 2004-12-27 2008-02-20 阿斯利康(瑞典)有限公司 作为代谢型谷氨酸受体激动剂用于治疗神经病学及精神病学病症的吡唑酮化合物
CN101309905A (zh) 2005-08-12 2008-11-19 阿斯利康(瑞典)有限公司 取代的异吲哚酮及其作为代谢型谷氨酸受体增效剂的用途

Also Published As

Publication number Publication date
EA201170227A1 (ru) 2011-06-30
SI2318375T1 (sl) 2012-11-30
PL2318375T3 (pl) 2013-02-28
TW201006801A (en) 2010-02-16
US7754742B2 (en) 2010-07-13
EP2318375A1 (en) 2011-05-11
CN102099344A (zh) 2011-06-15
EA018434B1 (ru) 2013-07-30
KR101287713B1 (ko) 2013-07-23
KR20110022676A (ko) 2011-03-07
CY1113315T1 (el) 2016-04-13
CA2731215C (en) 2013-08-27
US20100016373A1 (en) 2010-01-21
CA2731215A1 (en) 2010-01-21
JP5379227B2 (ja) 2013-12-25
CN102099344B (zh) 2013-10-30
MX2011000611A (es) 2011-03-01
BRPI0915977A2 (pt) 2018-10-30
AR074631A1 (es) 2011-02-02
JP2011528658A (ja) 2011-11-24
ES2393243T3 (es) 2012-12-19
DK2318375T3 (da) 2012-10-08
HRP20120830T1 (hr) 2012-11-30
WO2010009062A1 (en) 2010-01-21
EP2318375B1 (en) 2012-09-19
AU2009271105A1 (en) 2010-01-21

Similar Documents

Publication Publication Date Title
ES2393243T3 (es) Imidazol carboxamidas
ES2319107T3 (es) Derivados de 5-halo-triptamina usados como ligandos de los receptores de serotonina 5-ht6 y/o 5-ht7.
TWI837169B (zh) 甲狀腺素受體β促效劑化合物
KR900004384B1 (ko) 복소환식 아미드 유도체 및 그 제조방법
PT701819E (pt) Novas composicoes contendo sertralina e um agonista ou antagonista de receptor de 5-ht1d
CA2642610A1 (en) Amide derivative or salt thereof
CN101679397A (zh) 具有nos抑制活性的喹诺酮、四氢喹啉及其相关化合物
NO326690B1 (no) Nye arylsusfonamidforbindelser for behandlingen av fedme og type II diabetes, fremgangsmåte for fremstilling derav, samt farmasøytiske formuleringer som inneholder slike
JP2006505559A (ja) 5−ht6受容体親和性を持つ4−ピペラジニルベンゼンスルホニルインドール
BR112013000783A2 (pt) derivados arilamídicos tendo propriedades antiandrogênicas
ES2434250T3 (es) Compuestos de 3-(fenoxifenilmetil)pirrolidina
KR900004385B1 (ko) 카복사미드 유도체 및 그의 제조방법
NL1029919C2 (nl) Therapeutische difenyletherliganden.
US20200270214A1 (en) NADPH Oxidase Inhibitors and Uses Thereof
CN108084153A (zh) 吡啶基硫代乙酸化合物、组合物及其应用
JPH11513376A (ja) 選択的β▲下3▼−アドレナリン作動剤
BR112020004419A2 (pt) formas sólidas de 2-(5-(4-(2-morfolinoetóxi)fenil)piridin-2-il)-n-benzilacetamida
JPH02178263A (ja) アザアズレン誘導体、その製造法およびそれを有効成分とする抗アレルギー剤および抗炎症剤
JPH06508378A (ja) 新規アミドアルキル−およびイミドアルキル−ピペラジン類
AU2009271105B2 (en) Imidazole carboxamides
US5179112A (en) Heterocyclic amide derivatives and pharmaceutical use
JP2026067759A (ja) C3a受容体拮抗化合物及びその利用
TW201623244A (zh) 包含硫基團之4,5-二氫-1h-吡唑-3-甲脒衍生物、其製備方法以及包含其之藥學組成物
HK40075686A (en) Estrogen receptor-modulating compounds
HK1140754A (en) Quinolone and tetrahydroquinoline and related compounds having nos inhibitory activity